The CXCL12 G801A polymorphism and cancer risk: evidence from 17 case-control studies.
CXCL12 has been implicated in human carcinogenesis, but the association between the most-studied G801A polymorphism (rs1801157) and the risk of various cancers was reported with inconclusive results. The aim of this study was to assess the association between the CXCL12 G801A polymorphism and cancer risk. A meta-analysis of 17 studies with 3048 cancer patients and 4522 controls was conducted to evaluate the strength of the association using odds ratio (OR) with its 95% confidence interval (CI). The overall results showed that the variant genotypes were associated with a significantly increased risk of all cancer types (OR=1.38, 95%CI=1.18-1.61 for GA versus GG, and OR=1.36, 95%CI=1.17-1.59 for GA/AA versus GG). In the stratified analyses, there was a significantly increased risk for the studies of breast cancer (OR=1.64, 95% CI=1.16-2.33 for AA versus GG, OR=1.42, 95%CI=1.18-1.71 for GA versus GG, and OR=1.44, 95%CI=1.21-1.72 for GA/AA versus GG) and lung cancer (OR=2.86, 95% CI=1.75-4.69 for AA versus GG, OR=1.62, 95% CI=1.20-2.18 for GA vs. GG, OR=1.80, 95% CI=1.36-2.39 for GA/AA versus GG, and OR=2.24, 95%CI=1.41-3.57 for AA versus GA/GG), which remained for the studies of Asian populations and hospital-based control sources. Although some modest bias could not be eliminated, this meta-analysis indicates that the CXCL12 G801A polymorphism is a low-penetrance risk factor for cancer development.